ストックスクリーナーアプリを入手
5.00
4.40%
-0.23
アフターアワーズ：
4.98
-0.02
-0.40%
前日終値:
$5.23
開ける：
$5.06
24時間の取引高:
135.33K
Relative Volume:
0.36
時価総額：
$36.05M
収益：
$151.93M
当期純損益:
$23.40M
株価収益率:
2.2808
EPS:
2.1922
ネットキャッシュフロー:
$-69.80M
1週間 パフォーマンス:
-19.74%
1か月 パフォーマンス:
+12.87%
6か月 パフォーマンス:
-58.57%
1年 パフォーマンス:
-28.77%
1日の値動き範囲:
$4.82
$5.2134
1週間の範囲:
$4.82
$7.0699
52週間の値動き範囲:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
名前
Atara Biotherapeutics Inc
セクター
電話
805-623-4211
住所
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
5.00 | 42.32M | 151.93M | 23.40M | -69.80M | 2.1922 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-13 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2023-11-09 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-20 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-07-13 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-07-13 | ダウングレード | Stifel | Buy → Hold |
| 2022-05-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-05-13 | アップグレード | JP Morgan | Neutral → Overweight |
| 2020-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-12-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-10 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-30 | 開始されました | Evercore ISI | Outperform |
| 2020-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-23 | アップグレード | Citigroup | Neutral → Buy |
| 2019-11-08 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-09-27 | ダウングレード | Goldman | Neutral → Sell |
| 2019-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2019-06-04 | アップグレード | Citigroup | Sell → Neutral |
| 2019-05-30 | 開始されました | ROTH Capital | Buy |
| 2019-05-23 | 開始されました | Stifel | Buy |
| 2019-01-23 | 開始されました | Mizuho | Buy |
| 2018-04-10 | 開始されました | JP Morgan | Overweight |
| 2018-03-16 | 開始されました | Guggenheim | Neutral |
| 2018-03-05 | 繰り返されました | Jefferies | Buy |
| 2018-02-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | ダウングレード | Citigroup | Neutral → Sell |
| 2018-01-03 | アップグレード | Citigroup | Sell → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Atara Biotherapeutics Inc (ATRA) 最新ニュース
What are analysts price targets for Atara Biotherapeutics Inc2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
[S-3] Atara Biotherapeutics, Inc. Shelf Registration Statement | ATRA SEC FilingForm S-3 - Stock Titan
Market Recap: Will Atara Biotherapeutics Inc benefit from AI trendsEarnings Trend Report & Weekly Momentum Stock Picks - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application - Investing.com Nigeria
Atara Biotherapeutics, Inc. 2025 Annual Report: Strategic Alternatives, Business Overview, and Risk Factors - Minichart
Atara Biotherapeutics: Q4 Loss & Annual Profit 2025 Financial ResultsNews and Statistics - IndexBox
Atara Biotherapeutics: Q4 Earnings Snapshot - KTVB
Atara Biotherapeutics (NASDAQ: ATRA) registers $11.1M ATM offering via TD Cowen - Stock Titan
Atara Biotherapeutics (ATRA) bets on tab-cel as layoffs, FDA pushback mount - Stock Titan
Atara (NASDAQ: ATRA) turns 2025 profit and targets cash runway into 2026 - Stock Titan
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - The Joplin Globe
Atara Biotherapeutics: Fourth Quarter Earnings Overview - Bitget
Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” - The Cancer Letter
Weekly Trades: Will Atara Biotherapeutics Inc benefit from AI trendsQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel - marketscreener.com
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus
Atara Plans FDA Type A Meeting on EBVALLO - TipRanks
Atara Biotherapeutics schedules FDA Type A meeting on EBVALLO BLA complete response - TradingView
FDA to hold Type A meeting on Atara Biotherapeutics (ATRA) EBVALLO tab-cel BLA - Stock Titan
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire
Atara (ATRA) CEO granted 81,100 RSUs, now holds 143,078 shares - Stock Titan
Atara Biotherapeutics (ATRA) awards 20,300 RSUs to Chief Accounting Officer - Stock Titan
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus - TechStock²
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aug Closing: Can Atara Biotherapeutics Inc sustain earnings growth2026 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Chart Watch: Is Atara Biotherapeutics Inc being accumulated by smart moneyJobs Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Why Atara Biotherapeutics Inc. stock is popular among millennials2025 Trading Recap & Verified Entry Point Signals - Naître et grandir
Aug Momentum: Is Atara Biotherapeutics Inc forming a breakout patternJuly 2025 Catalysts & Short-Term Swing Trade Alerts - baoquankhu1.vn
Profit Review: Will Atara Biotherapeutics Inc benefit from green energy policiesEarnings Recap Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection - Stocktwits
Atara Biotherapeutics (ATRA) CEO sells 2,996 shares to cover RSU taxes - Stock Titan
Atara Biotherapeutics provides regulatory update on tabelecleucel - marketscreener.com
Atara, Pierre Fabre seek FDA meeting on EBVALLO - TipRanks
Atara Biotherapeutics (ATRA) and Partner Seek FDA Meeting for Ta - GuruFocus
Atara Biotherapeutics partner seeks Type A FDA meeting on tabelecleucel following CRL - TradingView
Atara Biotherapeutics (ATRA) requests FDA Type A meeting on EBVALLO™ - Stock Titan
Atara Biotherapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Insider sale: ATRA (NASDAQ: ATRA) 7,788 RSU shares settled 03/01/2026 - Stock Titan
ATRA (NASDAQ) insider resale notice: 4,759 RSU shares reported - Stock Titan
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ATRA Should I Buy - Intellectia AI
Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection - GuruFocus
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Market Overview: Can Atara Biotherapeutics Inc stock double in the next yearStock Surge & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Atara extends $9M milestone payment deadline to 2028 By Investing.com - Investing.com Australia
Atara Biotherapeutics Provides a Business Update - BioSpace
Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement - GuruFocus
Atara Biotherapeutics Inc (ATRA) 財務データ
収益
当期純利益
現金流量
EPS
0.69%
大文字化:
|
ボリューム (24 時間):